Company intelligence / Profile preview

OmniaBio

Hamilton, Ontario, Canadaomniabio.com ↗

Ownership: Private
Development stage: Commercial

Overview

OmniaBio operates North America's largest cell and gene therapy CDMO facility, providing process development, GMP manufacturing, analytical development, and regulatory support for advanced therapeutics. The company leverages AI, robotics, and automation to improve efficiency and quality. Its first commercial-stage program involves manufacturing CARTISTEM for Medipost—a stem cell therapy for knee cartilage defects in osteoarthritis patients.

Therapeutic areas: OncologyEndocrinologyRheumatologyCardiovascularNeurology
Modalities: Cell therapiesGene therapiesGene-modified cellsViral vectorsStem cell-based therapies
Industry: Contract Manufacturing Organization

Partnerships

MedipostInvest Ontario

Beyond the preview

Go deeper on OmniaBio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OmniaBio.

Explore the full profile